Scientists build lab models of scleroderma from Patients' blood cells

NCT ID NCT07650565

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to create stem cell lines from blood samples of 16 people: 4 with severe scleroderma, 4 with mild scleroderma, and 8 of their healthy relatives. These stem cells will be turned into various tissue types (like heart, skin, and immune cells) in the lab to study how the disease works at a cellular level. The goal is to better understand the differences between severe and mild forms of scleroderma, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could reveal why scleroderma affects people differently and point toward new treatment targets.
What could go wrong: This is a very early, small study (16 people) focused on building lab models, not testing treatments. It may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

University hospital Montpellier

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.